A randomized double-blind placebo-controlled first-in-man single-dose and multiple dose study to evaluate the safety, tolerability and efficacy of a recombinant chimeric bacteriophage endolysin HY-133 with an extended phase to evaluate effects of the nasal microbiome

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507737-17-00

Acronym

HY-133

Enrollment

Registered

2024-03-28

Start date

2024-07-10

Completion date

Unknown

Last updated

2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasal colonization with methicillin-susceptible Staphylococcus aureus (MSSA)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026